Author:
Prosperi Mattia CF,Bracciale Laura,Fabbiani Massimiliano,Di Giambenedetto Simona,Razzolini Francesca,Meini Genny,Colafigli Manuela,Marzocchetti Angela,Cauda Roberto,Zazzi Maurizio,De Luca Andrea
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference44 articles.
1. Sayana S, Khanlou H: Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther. 2009, 7 (1): 9-19. 10.1586/14787210.7.1.9.
2. Heera J, Ive P, Botes M, Dejesus E, Mayer H, Goodrich J, Clumeck N, Cooper DA, Walmsley S, Craig C, Reeves J, van der Ryst E, Saag M: The MERIT study of maraviroc in antiretroviral-naive patients with R5 HIV-1: 96-week results [abstract]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa. 2009
3. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E, MOTIVATE 1 and MOTIVATE 2 Study Teams: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008, 359 (14): 1442-55. 10.1056/NEJMoa0803154.
4. Vandekerckhove L, Verhofstede C, Vogelaers D: Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. J Antimicrob Chemother. 2009, 63 (6): 1087-96. 10.1093/jac/dkp113.
5. Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H, A4001029 Study Group: A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009, 199 (11): 1638-47. 10.1086/598965.
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献